Success Metrics

Clinical Success Rate

66.7%

Based on 2 completed trials

Completion Rate

67%(2/3)

Active Trials

0(0%)

Results Posted

0%(0 trials)

Terminated

1(33%)

Phase Distribution

Ph not_applicable

33%

Ph phase_1

67%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 1Safety & dosage

2(66.7%)

N/ANon-phased studies

1(33.3%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(2)

Terminated(1)

Detailed Status

Completed2

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

66.7%

Most Advanced

Phase 1

Trials by Phase

Phase 12 (66.7%)

N/A1 (33.3%)

Trials by Status

completed267%

terminated133%

Recent Activity

0 active trials

Showing 3 of 3

completednot_applicable

Activation of the Endocannabinoid System and Cognition

NCT05226351

completedphase_1

Bioavailability, Bioequivalence and Tolerability of IHL-42X Compared to the Reference Drugs

NCT05857384

terminatedphase_1

Dronabinol for Pain and Inflammation in Adults Living With Sickle Cell Disease

NCT03978156

Clinical Trials (3)

Showing 3 of 3 trials

NCT05226351Not Applicable

Activation of the Endocannabinoid System and Cognition

Completed

NCT05857384Phase 1

Bioavailability, Bioequivalence and Tolerability of IHL-42X Compared to the Reference Drugs

Completed

NCT03978156Phase 1

Dronabinol for Pain and Inflammation in Adults Living With Sickle Cell Disease

Terminated

All 3 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 3